Cancer52 has worked in partnership with the Patient Information Forum (PIF) and National Rheumatoid Arthritis Society (NRAS) to conduct a survey on Fair Market Value (FMV). The survey captured patient organisations’ experience of payments set to FMV; the rate set by pharmaceutical companies for the work of patients and the staff of patient organisations.
The results found 70% of organisations felt FMV payments were inconsistent across pharmaceutical companies. There was a high level of support for a FMV ‘rate card’, 84% of organisations felt it would be helpful.
Please see a summary of the results.
Comments